# Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas

> **NCT00003564** · PHASE3 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** Isotretinoin
- **DRUG:** Procarbazine Hydrochloride

## Key facts

- **NCT ID:** NCT00003564
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn.
- **Last updated:** 2012-02-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003564, "Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00003564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*